Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease

A. Jirásková, G. Bortolussi, G. Dostálová, L. Eremiášová, L. Golaň, V. Danzig, A. Linhart, L. Vítek,

. 2017 ; 2017 (-) : 9478946. [pub] 20170816

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024621

The aim of our study was to assess the possible relationships among heme oxygenase (HMOX), bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations, serum bilirubin levels, and Fabry disease (FD). The study included 56 patients with FD (M : F ratio = 0.65) and 185 healthy individuals. Complete standard laboratory and clinical work-up was performed on all subjects, together with the determination of total peroxyl radical-scavenging capacity. The (GT)n and (TA)n dinucleotide variations in the HMOX1 and UGT1A1 gene promoters, respectively, were determined by DNA fragment analysis. Compared to controls, patients with FD had substantially lower serum bilirubin levels (12.0 versus 8.85 μmol/L, p = 0.003) and also total antioxidant capacity (p < 0.05), which showed a close positive relationship with serum bilirubin levels (p = 0.067) and the use of enzyme replacement therapy (p = 0.036). There was no association between HMOX1 gene promoter polymorphism and manifestation of FD. However, the presence of the TA7 allele UGT1A1 gene promoter, responsible for higher systemic bilirubin levels, was associated with a twofold lower risk of manifestation of FD (OR = 0.51, 95% CI = 0.27-0.97, p = 0.038). Markedly lower serum bilirubin levels in FD patients seem to be due to bilirubin consumption during increased oxidative stress, although UGT1A1 promoter gene polymorphism may modify the manifestation of FD as well.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024621
003      
CZ-PrNML
005      
20180718105506.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2017/9478946 $2 doi
035    __
$a (PubMed)28951772
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jirásková, Alena $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
245    10
$a Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease / $c A. Jirásková, G. Bortolussi, G. Dostálová, L. Eremiášová, L. Golaň, V. Danzig, A. Linhart, L. Vítek,
520    9_
$a The aim of our study was to assess the possible relationships among heme oxygenase (HMOX), bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations, serum bilirubin levels, and Fabry disease (FD). The study included 56 patients with FD (M : F ratio = 0.65) and 185 healthy individuals. Complete standard laboratory and clinical work-up was performed on all subjects, together with the determination of total peroxyl radical-scavenging capacity. The (GT)n and (TA)n dinucleotide variations in the HMOX1 and UGT1A1 gene promoters, respectively, were determined by DNA fragment analysis. Compared to controls, patients with FD had substantially lower serum bilirubin levels (12.0 versus 8.85 μmol/L, p = 0.003) and also total antioxidant capacity (p < 0.05), which showed a close positive relationship with serum bilirubin levels (p = 0.067) and the use of enzyme replacement therapy (p = 0.036). There was no association between HMOX1 gene promoter polymorphism and manifestation of FD. However, the presence of the TA7 allele UGT1A1 gene promoter, responsible for higher systemic bilirubin levels, was associated with a twofold lower risk of manifestation of FD (OR = 0.51, 95% CI = 0.27-0.97, p = 0.038). Markedly lower serum bilirubin levels in FD patients seem to be due to bilirubin consumption during increased oxidative stress, although UGT1A1 promoter gene polymorphism may modify the manifestation of FD as well.
650    _2
$a dospělí $7 D000328
650    _2
$a antioxidancia $x metabolismus $7 D000975
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a Fabryho nemoc $x krev $x enzymologie $x genetika $7 D000795
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glukuronosyltransferasa $x genetika $7 D014453
650    _2
$a hemoxygenasa-1 $x genetika $7 D051547
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a polymorfismus genetický $7 D011110
650    _2
$a promotorové oblasti (genetika) $7 D011401
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bortolussi, Giulia $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
700    1_
$a Dostálová, Gabriela $u 2nd Department of Internal Medicine and Department of Cardiovascular Medicine, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
700    1_
$a Eremiášová, Lenka $u 2nd Department of Internal Medicine and Department of Cardiovascular Medicine, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
700    1_
$a Golaň, Lubor $u 2nd Department of Internal Medicine and Department of Cardiovascular Medicine, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
700    1_
$a Danzig, Vilém $u 2nd Department of Internal Medicine and Department of Cardiovascular Medicine, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
700    1_
$a Linhart, Aleš $u 2nd Department of Internal Medicine and Department of Cardiovascular Medicine, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
700    1_
$a Vítek, Libor $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic. 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Katerinska 32, 12000 Prague 2, Czech Republic.
773    0_
$w MED00180520 $t Oxidative medicine and cellular longevity $x 1942-0994 $g Roč. 2017, č. - (2017), s. 9478946
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28951772 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180718105806 $b ABA008
999    __
$a ok $b bmc $g 1316752 $s 1021542
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 2017 $c - $d 9478946 $e 20170816 $i 1942-0994 $m Oxidative medicine and cellular longevity $n Oxid Med Cell Longev $x MED00180520
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace